CHPF2

Across TCGA pan-cancer cohorts, CHPF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHPF2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHPF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHPF2 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LSCC are the cancer types where CHPF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.251	0.509	<.001	45	view →
CCRCC	DFS	Tertile	III,IV	0.452	1.000	.028	6	view →
LSCC	OS	Quartile	II,III,IV	0.783	1.000	.021	3	view →
UCEC	OS	Median	All	0.896	0.986	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHPF2–PDAC (DFS)

Open the PDAC breakdown →